Table 1 Patient Characteristics
From: Oral Pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study
Age | Gender | Tumor Location | Radiation Dose (Gy) | Time from Completion of Radiation (Months) | ROM Impairment at Baseline | Duration of Pirfenidone Treatment (Months) |
|---|---|---|---|---|---|---|
60 | M | Head and Neck | 63 | 46.0 | Decreased Cervical ROM | 25.0 |
60 | M | Head and Neck | 72 | 32.1 | Decreased Cervical ROM | 24.6 |
54 | M | Hodgkin's | 45 – Pelvis 36 – PA | 198.8 | Decreased LE ROM and Strength | 24.0 |
59 | M | Head and Neck | 70.2 | 53.7 | Decreased UE and Cervical ROM | 23.3 |
56 | M | Head and Neck | 60 | 69.1 | Decreased UE and Cervical ROM | 22.4 |
53 | M | Hodgkin's | 54 – Mantle 36 – PA | 276.5 | Decreased Cervical ROM | 6.3 (removed from study) |
60 | M | Head and Neck | 70 | 23.4 | Decreased Cervical ROM | 3.0 (removed from study) |